KRAS and cancer: Because concurrent KRAS and TP53 mutations manifest potentially synergistic biologic effects, cancers carrying both KRAS and TP53 mutations (KRAS+/TP53+) might represent a unique cancer subtype with distinct and aggressive biologic behaviors [16].